Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about MEDP, unsubscribe in one click. Privacy
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Invimestrocel | Ischemic Stroke | Phase 3 · NCT03545607 | Terminated |
| Lerodalcibep | Familial Hypercholesterolemia - Heterozygous | Phase 3 · NCT07102511 | Enrolling by invitation |
| TNX-103 | Pulmonary Hypertension | Phase 3 · NCT05983250 | Active not recruiting |
| Investigator's choice | HSV Infection | Phase 3 · NCT03073967 | Completed |
| Etripamil Test Dose | Paroxysmal Supraventricular Tachycardia | Phase 3 · NCT03464019 | Terminated |
| Etripamil NS 70 mg | Paroxysmal Supraventricular Tachycardia | Phase 3 · NCT03635996 | Terminated |
| Dalcetrapib | Acute Coronary Syndrome | Phase 3 · NCT02525939 | Completed |
| Cefepime-zidebactam (FEP-ZID) | Complicated Urinary Tract Infection | Phase 3 · NCT04979806 | Completed |
| Pritelivir (AIC316) | HSV Infection | Phase 3 · NCT03073967 | Completed |
| Rugonersen | Angelman Syndrome | Phase 3 · NCT07605429 | Recruiting |
| Sevasemten | Becker Muscular Dystrophy | Phase 2 · NCT06066580 | Enrolling by invitation |
| Dapolsertib | Acute Myeloid Leukemia | Phase 1/2 · NCT03008187 | Completed |
| Levosimendan | Hypertension Pulmonary Secondary Heart Failure | Phase 2 · NCT03624010 | Completed |
| RAD101 (18F-FPIA) | Brain Metastases From Solid Tumors | Phase 2 · NCT06777433 | Active not recruiting |
| Tomivosertib | Non-small Cell Lung Cancer | Phase 2 · NCT04622007 | Unknown |
| ETC-1002 | Hypercholesterolemia | Phase 2 · NCT02178098 | Completed |
Also used in these trials (approved or third-party drugs, not MEDP's own candidates): Spinosad, Inclisiran, Etripamil, Meropenem, Pembrolizumab, Pemetrexed Disodium, Triamcinolone Acetonide Extended-Release Injectable, Valacyclovir, Supra-pharmacologic Dexamethasone Sodium Phosphate AVM0703, Avacopan, Toripalimab, Tocilizumab.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
MEDP holds $705.3M in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.
Dilution pressure: 0 · Low
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when MEDP files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| August J. Troendle President & CEO, Director, 10% owner · +30,000 options |
Insider | 5,071,244 | 18.13% | 2026-09-29 |
| AQR Capital Management, LLC | Institution (13G, 5%+) | 1,396,654 | 4.99% | 2026-09-30 |
| Susan E Burwig Exec. VP, Operations · +15,000 options |
Insider | 54,012 | 0.19% | 2026-10-26 |
| Brian T Carley Director · +1,145 options |
Insider | 27,861 | 0.10% | 2026-09-30 |
| Stephen P Ewald General Counsel & Corp. Secy. · +15,000 options |
Insider | 19,098 | 0.07% | 2026-10-29 |
| Kevin M. Brady CFO & Treasurer · +3,403 options |
Insider | 12,830 | 0.05% | 2026-08-20 |
| Cornelius P. III McCarthy Director · +1,138 options |
Insider | 12,303 | 0.04% | 2026-09-30 |
| Fred B Jr Davenport Director · +1,110 options |
Insider | 5,798 | 0.02% | 2026-08-19 |
| Robert O. Kraft Director · +1,142 options |
Insider | 987 | 0.00% | 2026-09-30 |
| Brad W. Hansman Exec. VP, Operations |
Insider | 697 | 0.00% | 2026-06-01 |
Share count 27,971,686 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for MEDP and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →